文献速递泌尿生殖介入PETMRCT

评估生化复发前列腺癌:18F-DCFPyL PET/CT的组织学验证及与多参数MRI的比较

Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of 18F-DCFPyL PET/CT with Comparison to Multiparametric MRI.
PubMed 文献 · Radiology · 2020-07-07

研究前瞻性纳入根治性治疗后生化复发且常规影像阴性的前列腺癌男性,比较18F-DCFPyL PET/CT与3.0T盆腔多参数MRI,并以组织学验证。18F-DCFPyL显示更多盆腔淋巴结,组织学验证敏感度69%、特异度91%、阳性预测值86%,特异度和阳性预测值较高;联合多参数MRI可提高阳性预测值。

要点

  • 18F-DCFPyL PET/CT组织学验证敏感度69%、特异度91%、阳性预测值86%。
  • 18F-DCFPyL检出盆腔淋巴结128枚,多于多参数MRI的23枚。
  • 联合多参数MRI后阳性预测值整体提高38%(P=.02)。

核心结论

  • 18F-DCFPyL PET/CT结果经组织学验证,显示高特异度和阳性预测值。
  • 在盆腔,18F-DCFPyL检出更多淋巴结,联合多参数MRI后阳性预测值和特异度提高。

研究设计与样本

  • 前瞻性招募根治性前列腺切除和/或放疗后生化复发、常规影像(骨扫描和/或CT)阴性且PSA中位2.27 ng/mL(范围0.2-27.45 ng/mL)的男性。
  • 参与者接受18F-DCFPyL PET/CT和3.0T盆腔多参数MRI检查。
  • 统计方法包括Wald检验和改良χ2检验。

关键影像表现/征象

  • 18F-DCFPyL或多参数MRI在77名男性中显示323个病灶,所有MRI视野内病灶的影像检出一致率为25%(82/323),仅评估前列腺床病灶时一致率为53%(52/99)。
  • 18F-DCFPyL显示盆腔淋巴结128枚,多参数MRI显示23枚。

诊断标准与关键数值

  • 18F-DCFPyL组织学验证(80个部位):敏感度69%(25/36;95%CI:51%,88%),特异度91%(40/44;95%CI:74%,98%),阳性预测值86%(25/29;95%CI:73%,97%)。
  • 多参数MRI组织学验证:敏感度69%(24/35;95%CI:50%,86%),特异度74%(31/42;95%CI:42%,89%),阳性预测值69%(24/35;95%CI:50%,88%);与18F-DCFPyL比较P值分别为.95、.14、.07。
  • 前列腺床18F-DCFPyL:敏感度57%(13/23;95%CI:32%,81%),特异度86%(18/21;95%CI:73%,100%),阳性预测值81%(13/16;95%CI:59%,100%)。
  • 前列腺床多参数MRI:敏感度83%(19/23;95%CI:59%,100%),特异度52%(11/21;95%CI:29%,74%),阳性预测值66%(19/29;95%CI:44%,86%);与18F-DCFPyL比较P值分别为.19、.02、.17。
  • 18F-DCFPyL联合多参数MRI后阳性预测值整体提高38%(P=.02),前列腺床提高30%(P=.09)。

临床应用与阅片要点

  • 18F-DCFPyL PET/CT可检出更多盆腔淋巴结,联合多参数MRI可提高阳性预测值。
  • 前列腺床病灶中,18F-DCFPyL特异度高于多参数MRI(86% vs 52%,P=.02),但敏感度较低(57% vs 83%,P=.19)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Prostate cancer recurrence is found in up to 40% of men with prior definitive (total prostatectomy or whole-prostate radiation) treatment. Prostate-specific membrane antigen PET agents such as 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) may improve detection of recurrence compared with multiparametric MRI; however, histopathologic validation is lacking. Purpose To determine the sensitivity, specificity, and positive predictive value (PPV) of 18F-DCFPyL PET/CT based on histologic analysis and to compare with pelvic multiparametric MRI in men with biochemically recurrent prostate cancer. Materials and Methods Men were prospectively recruited after prostatectomy and/or radiation therapy with rising prostate-specific antigen level (median, 2.27 ng/mL; range, 0.2-27.45 ng/mL) and a negative result at conventional imaging (bone scan and/or CT). Participants underwent 18F-DCFPyL PET/CT imaging and 3.0-T pelvic multiparametric MRI. Statistical analysis included Wald and modified χ2 tests. Results A total of 323 lesions were visualized in 77 men by using 18F-DCFPyL or multiparametric MRI, with imaging detection concordance of 25% (82 of 323) when including all lesions in the MRI field of view and 53% (52 of 99) when only assessing prostate bed lesions. 18F-DCFPyL depicted more pelvic lymph nodes than did MRI (128 vs 23 nodes). Histologic validation was obtained in 80 locations with sensitivity, specificity, and PPV of 69% (25 of 36; 95% confidence interval [CI]: 51%, 88%), 91% (40 of 44; 95% CI: 74%, 98%), and 86% (25 of 29; 95% CI: 73%, 97%) for 18F-DCFPyL and 69% (24 of 35; 95% CI: 50%, 86%), 74% (31 of 42; 95% CI: 42%, 89%), and 69% (24 of 35; 95% CI: 50%, 88%) for multiparametric MRI (P = .95, P = .14, and P = .07, respectively). In the prostate bed, sensitivity, specificity, and PPV were 57% (13 of 23; 95% CI: 32%, 81%), 86% (18 of 21; 95% CI: 73%, 100%), and 81% (13 of 16; 95% CI: 59%, 100%) for 18F-DCFPyL and 83% (19 of 23; 95% CI: 59%, 100%), 52% (11 of 21; 95% CI: 29%, 74%), and 66% (19 of 29; 95% CI: 44%, 86%) for multiparametric MRI (P = .19, P = .02, and P = .17, respectively). The addition of 18F-DCFPyL to multiparametric MRI improved PPV by 38% overall (P = .02) and by 30% (P = .09) in the prostate bed. Conclusion Findings with 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) were histologically validated and demonstrated high specificity and positive predictive value. In the pelvis, 18F-DCFPyL depicted more lymph nodes and improved positive predictive value and specificity when added to multiparametric MRI. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Zukotynski and Rowe in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Lindenberg L, Mena E, Turkbey B, et al. Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of 18F-DCFPyL PET/CT with Comparison to Multiparametric MRI. Radiology. 2020. PMID: 32633674. doi:10.1148/radiol.2020192018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。